Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28874901 | 0.79 | RXRA (0.37) | KDM4EPOLBMAPTRECQLL3MBTL1 | |
| SCHEMBL29026122 | 0.78 | — | — | |
| SCHEMBL22654555 | 0.75 | — | — | |
| SCHEMBL138960 | 0.75 | — | — | |
| SCHEMBL6406085 | 0.74 | HIF1A (0.36) | ACHE | |
| SCHEMBL30121669 | 0.71 | — | — | |
| SCHEMBL28806289 | 0.71 | ALDH1A1 (0.37) | KDM4EMEN1ALDH1A1MAPTHTT | |
| SCHEMBL332826 | 0.71 | ACHE (0.31) | ELANEACHE | |
| SCHEMBL8988852 | 0.70 | — | — | |
| SCHEMBL20291479 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116120250-A | Method for preparing melamine phosphate and melamine polyphosphate from iron phosphate slag | 安徽南都华铂新材料科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-109235048-A | A kind of preparation method of fire-retardant air duct cloth material | 孝感寰誉新材科技有限公司 | 2019-01-18 | — | — | CN | claimed |
| EP-0191409-B1 | SLIP CASTING METHOD | HITACHI, LTD. (JP) | 1989-12-20 | — | — | EP | claimed |
| CN-114609865-B | Photosensitive coloring resin composition, color filter using same and display device | 住华科技股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240358783-A1 | METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT | LCT TECHNOLOGIES LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4313007-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | Lyfe CHNG, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-116120250-A | Method for preparing melamine phosphate and melamine polyphosphate from iron phosphate slag | 安徽南都华铂新材料科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20230026731-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | LCT TECHNOLOGIES LLC | 2023-01-26 | — | — | US | disclosed |
| WO-2022221072-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022212789-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-114853975-A | UV-cured water-based silicon-containing polyurethane and preparation method thereof | 广州海豚新材料有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-0276436-B1 | PHOSPHINIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-16 | — | — | EP | disclosed |
| CN-1017337-B | PROCESS FOR PREPARING PHOSPHINIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1992-07-08 | — | — | CN | disclosed |
| US-5006651-A | Rheumatic diseases, bone disorders | HOFFMAN-LA ROCHE INC. (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0191409-B1 | SLIP CASTING METHOD | HITACHI, LTD. (JP) | 1989-12-20 | — | — | EP | disclosed |
| US-4885283-A | Phosphinic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1989-12-05 | — | — | US | disclosed |
| US-4871497-A | Slip casting method | HITACHI, LTD. (JP) | 1989-10-03 | — | — | US | disclosed |
| EP-0276436-A1 | Phosphinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-08-03 | — | — | EP | disclosed |
| CN-87101164-A | PHOSPHINIC ACID DERIVATIVES | — | 1988-06-29 | — | — | CN | disclosed |
| EP-0191409-A1 | Slip casting method | HITACHI, LTD. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026731-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | HTR7, HTR6, PNMT | ELANE 4195/4885KDM4E 1479/4885MEN1 1233/4885 |
| US-20240358783-A1 | METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT | HTR7, HTR6, PNMT | ELANE 4115/4885KDM4E 1602/4885MEN1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.